Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health

Federal funding opportunity PAR-25-226 published by National Institutes of Health. Review the official synopsis for eligibility, award terms, and application requirements.